BioCentury
ARTICLE | Company News

AmorChem, Hopital Maisonneuve-Rosemont deal

June 30, 2014 7:00 AM UTC

Life science VC fund AmorChem partnered with the hospital and its tech transfer arm Univalor to discover inhibitors of semaphorin 3A (SEMA3A) to treat diabetic macular edema (DME). AmorChem made an u...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article